{
    "hands_on_practices": [
        {
            "introduction": "The interaction between a monoclonal antibody and its target is the cornerstone of its therapeutic effect. To quantify this interaction, we use key parameters like the equilibrium dissociation constant ($K_D$), which measures the affinity of the antibody for its target. This exercise will guide you through deriving $K_D$ from its fundamental kinetic components, the association ($k_{\\text{on}}$) and dissociation ($k_{\\text{off}}$) rates, and using it to predict receptor occupancy at a given antibody concentration .",
            "id": "4929203",
            "problem": "A biotechnology company is characterizing a therapeutic monoclonal antibody (mAb) that binds a single epitope on a cell surface receptor in a $1:1$ reversible interaction. Under conditions where the free antibody concentration is controlled and measurable, the binding can be modeled by the reversible reaction $R + A \\rightleftharpoons RA$, where $R$ is the free receptor, $A$ is the free antibody, and $RA$ is the receptor–antibody complex. Use the law of mass action at equilibrium and the standard kinetic definitions of the association rate constant $k_{\\text{on}}$ (units $\\text{M}^{-1}\\text{s}^{-1}$) and dissociation rate constant $k_{\\text{off}}$ (units $\\text{s}^{-1}$) to derive the equilibrium dissociation constant $K_D$ and the fractional receptor occupancy $\\theta$ in terms of the free antibody concentration $[A]$ for a single binding site without cooperativity.\n\nGiven $k_{\\text{on}} = 1 \\times 10^{5}\\,\\text{M}^{-1}\\text{s}^{-1}$ and $k_{\\text{off}} = 1 \\times 10^{-4}\\,\\text{s}^{-1}$, compute $K_D$ and predict the receptor occupancy at a free antibody concentration $[A] = 10\\,\\text{nM}$.\n\nExpress $K_D$ in nanomolar (nM), and express the receptor occupancy as a unitless decimal fraction. Round both to four significant figures. Provide your final answer as two values in a single row in the order $\\left(K_D\\text{ in nM},\\,\\theta\\right)$.",
            "solution": "The problem is validated as scientifically grounded, well-posed, objective, and complete. It represents a standard application of chemical kinetics to receptor pharmacology.\n\nThe task is to derive the equilibrium dissociation constant ($K_D$) and the fractional receptor occupancy ($\\theta$) for a single-site binding model, and then to compute their numerical values given specific rate constants and a ligand concentration.\n\nThe reversible reaction is given by:\n$$\nR + A \\rightleftharpoons RA\n$$\nwhere $R$ is the free receptor, $A$ is the free antibody (ligand), and $RA$ is the receptor-antibody complex. The binding is specified as a $1:1$ interaction.\n\nAccording to the law of mass action, the rate of the forward reaction (association) is proportional to the concentrations of the reactants:\n$$\n\\text{Rate}_{\\text{association}} = k_{\\text{on}} [R] [A]\n$$\nwhere $k_{\\text{on}}$ is the association rate constant with units of $\\text{M}^{-1}\\text{s}^{-1}$, $[R]$ is the molar concentration of free receptors, and $[A]$ is the molar concentration of free antibody.\n\nThe rate of the reverse reaction (dissociation) is proportional to the concentration of the product:\n$$\n\\text{Rate}_{\\text{dissociation}} = k_{\\text{off}} [RA]\n$$\nwhere $k_{\\text{off}}$ is the dissociation rate constant with units of $\\text{s}^{-1}$, and $[RA]$ is the molar concentration of the receptor-antibody complex.\n\nAt equilibrium, the rate of association equals the rate of dissociation:\n$$\nk_{\\text{on}} [R] [A] = k_{\\text{off}} [RA]\n$$\n\nThe equilibrium dissociation constant, $K_D$, is defined for the dissociation reaction $RA \\rightleftharpoons R + A$. It is the ratio of the product of the concentrations of the dissociated species to the concentration of the complex at equilibrium:\n$$\nK_D = \\frac{[R][A]}{[RA]}\n$$\nBy rearranging the equilibrium rate equation, we can express $K_D$ in terms of the rate constants:\n$$\n\\frac{[R][A]}{[RA]} = \\frac{k_{\\text{off}}}{k_{\\text{on}}}\n$$\nThus, the first required derivation is:\n$$\nK_D = \\frac{k_{\\text{off}}}{k_{\\text{on}}}\n$$\n\nNext, we derive the fractional receptor occupancy, $\\theta$. This is defined as the fraction of the total receptor population that is bound to the ligand. Let $[R_T]$ be the total concentration of receptors. Then:\n$$\n[R_T] = [R] + [RA]\n$$\nThe fractional occupancy $\\theta$ is:\n$$\n\\theta = \\frac{\\text{Concentration of bound receptors}}{\\text{Total concentration of receptors}} = \\frac{[RA]}{[R_T]} = \\frac{[RA]}{[R] + [RA]}\n$$\nTo express $\\theta$ in terms of $[A]$, we use the definition of $K_D$. Rearranging for $[R]$ gives:\n$$\n[R] = \\frac{K_D [RA]}{[A]}\n$$\nSubstitute this expression for $[R]$ into the equation for $\\theta$:\n$$\n\\theta = \\frac{[RA]}{\\left(\\frac{K_D [RA]}{[A]}\\right) + [RA]}\n$$\nFactor out $[RA]$ from the denominator:\n$$\n\\theta = \\frac{[RA]}{[RA]\\left(\\frac{K_D}{[A]} + 1\\right)}\n$$\nAssuming $[RA] \\ne 0$, we can cancel this term from the numerator and denominator:\n$$\n\\theta = \\frac{1}{\\frac{K_D}{[A]} + 1}\n$$\nMultiplying the numerator and denominator by $[A]$ yields the standard form of the Hill-Langmuir equation for a single non-cooperative binding site:\n$$\n\\theta = \\frac{[A]}{K_D + [A]}\n$$\n\nNow, we compute the numerical values.\nGiven:\n$k_{\\text{on}} = 1 \\times 10^{5}\\,\\text{M}^{-1}\\text{s}^{-1}$\n$k_{\\text{off}} = 1 \\times 10^{-4}\\,\\text{s}^{-1}$\n$[A] = 10\\,\\text{nM}$\n\nFirst, calculate $K_D$:\n$$\nK_D = \\frac{k_{\\text{off}}}{k_{\\text{on}}} = \\frac{1 \\times 10^{-4}\\,\\text{s}^{-1}}{1 \\times 10^{5}\\,\\text{M}^{-1}\\text{s}^{-1}} = 1 \\times 10^{-9}\\,\\text{M}\n$$\nThe problem requires $K_D$ to be expressed in nanomolar ($\\text{nM}$). We use the conversion $1\\,\\text{nM} = 10^{-9}\\,\\text{M}$.\n$$\nK_D = 1 \\times 10^{-9}\\,\\text{M} \\times \\frac{1\\,\\text{nM}}{10^{-9}\\,\\text{M}} = 1\\,\\text{nM}\n$$\nRounding to four significant figures as requested gives $1.000\\,\\text{nM}$.\n\nSecond, calculate the fractional occupancy $\\theta$ at $[A] = 10\\,\\text{nM}$. We use the derived expression for $\\theta$ with $K_D = 1\\,\\text{nM}$ and $[A] = 10\\,\\text{nM}$. It is crucial that $[A]$ and $K_D$ are in the same units.\n$$\n\\theta = \\frac{[A]}{K_D + [A]} = \\frac{10\\,\\text{nM}}{1\\,\\text{nM} + 10\\,\\text{nM}} = \\frac{10}{11}\n$$\nConverting this fraction to a decimal:\n$$\n\\theta \\approx 0.909090...\n$$\nRounding to four significant figures, we get $0.9091$.\n\nThe final answer requires the two values, $K_D$ in $\\text{nM}$ and the unitless fraction $\\theta$, in a single row.\nThe values are $K_D = 1.000$ and $\\theta = 0.9091$.",
            "answer": "$$\n\\boxed{\\begin{pmatrix} 1.000 & 0.9091 \\end{pmatrix}}\n$$"
        },
        {
            "introduction": "While target affinity determines a biologic's potency, its overall therapeutic effect depends on the total exposure the body receives over time, measured by the Area Under the Concentration-Time Curve (AUC). This exposure is critically influenced by the route of administration and the drug's bioavailability ($F$), which is the fraction of the dose that reaches systemic circulation. This practice explores the fundamental relationship between dose, bioavailability, and exposure, allowing you to calculate equivalent doses for intravenous (IV) and subcutaneous (SC) routes .",
            "id": "4929099",
            "problem": "A human Immunoglobulin G1 (IgG1) monoclonal antibody is administered as a single intravenous (IV) dose to a patient with linear pharmacokinetics over the therapeutic range. The Area Under the Concentration–Time Curve (AUC) is defined as the time integral of plasma concentration. Bioavailability $F$ is defined as the fraction of the administered dose that reaches the systemic circulation. Assume that systemic clearance is identical following intravenous and subcutaneous (SC) dosing, pharmacokinetics are linear, and the patient’s physiology is stable across dosing routes.\n\nA $70$ kg patient receives an IV dose of $10$ mg/kg. For the same patient and formulation, the SC bioavailability is measured as $F = 0.60$.\n\nUsing first principles based on the definitions above and the assumption of linear pharmacokinetics with identical clearance across routes, derive the relationship needed to match the SC exposure to the IV exposure and calculate the single SC dose that would produce the same AUC as the IV dose in this patient. Round your final numeric dose to three significant figures. Express the final dose in mg.\n\nFinally, briefly enumerate at least three scientifically plausible factors that can cause inter-patient variability in $F$ for subcutaneous dosing of monoclonal antibodies or fusion proteins, focusing on physiology or formulation rather than brand-specific details.",
            "solution": "The problem is valid as it is scientifically grounded in the principles of pharmacokinetics, is well-posed with sufficient and consistent information, and is expressed in objective, formal language. We can therefore proceed with the solution.\n\nThe core principle for a drug with linear pharmacokinetics is that the total systemic exposure, as measured by the Area Under the Concentration–Time Curve ($AUC$), is directly proportional to the amount of drug that reaches the systemic circulation and inversely proportional to the systemic clearance ($CL$). The amount of drug reaching the systemic circulation is the product of the administered dose ($Dose$) and the bioavailability ($F$). The relationship is expressed as:\n$$AUC = \\frac{F \\times Dose}{CL}$$\n\nWe are given two routes of administration: intravenous ($IV$) and subcutaneous ($SC$). Let's denote the parameters for each route with the corresponding subscripts.\n\nFor the intravenous ($IV$) route, the drug is administered directly into the systemic circulation. By definition, its bioavailability is absolute, meaning $F_{IV} = 1$. The $AUC$ for an $IV$ dose is:\n$$AUC_{IV} = \\frac{F_{IV} \\times Dose_{IV}}{CL} = \\frac{1 \\times Dose_{IV}}{CL}$$\n\nFor the subcutaneous ($SC$) route, the bioavailability $F_{SC}$ represents the fraction of the dose that is absorbed from the subcutaneous tissue into the systemic circulation. The $AUC$ for an $SC$ dose is:\n$$AUC_{SC} = \\frac{F_{SC} \\times Dose_{SC}}{CL}$$\n\nThe problem requires us to find the subcutaneous dose ($Dose_{SC}$) that produces the same exposure as the intravenous dose ($Dose_{IV}$). This means we must set $AUC_{SC} = AUC_{IV}$.\n$$\\frac{F_{SC} \\times Dose_{SC}}{CL} = \\frac{Dose_{IV}}{CL}$$\n\nThe problem states that systemic clearance ($CL$) is identical for both routes of administration. Since $CL$ must be a non-zero constant for the drug to be eliminated, we can cancel it from both sides of the equation. This yields the relationship needed to match the exposure between the two routes:\n$$F_{SC} \\times Dose_{SC} = Dose_{IV}$$\n\nThis equation is the derivation required by the first part of the problem. To find the required $SC$ dose, we rearrange this equation:\n$$Dose_{SC} = \\frac{Dose_{IV}}{F_{SC}}$$\n\nNow we will calculate the numerical value. The patient's mass is $m = 70 \\text{ kg}$ and the $IV$ dose is given as $10 \\text{ mg/kg}$. Therefore, the total $IV$ dose is:\n$$Dose_{IV} = 10 \\frac{\\text{mg}}{\\text{kg}} \\times 70 \\text{ kg} = 700 \\text{ mg}$$\n\nWe are given that the subcutaneous bioavailability is $F_{SC} = 0.60$. Substituting the values for $Dose_{IV}$ and $F_{SC}$ into our derived equation:\n$$Dose_{SC} = \\frac{700 \\text{ mg}}{0.60}$$\n$$Dose_{SC} = \\frac{700}{6/10} \\text{ mg} = \\frac{7000}{6} \\text{ mg} = \\frac{3500}{3} \\text{ mg} \\approx 1166.67 \\text{ mg}$$\n\nThe problem requires the final numeric dose to be rounded to three significant figures.\n$$Dose_{SC} \\approx 1170 \\text{ mg}$$\nThus, a single subcutaneous dose of $1170$ mg is required to produce the same total systemic exposure (AUC) as a $700$ mg intravenous dose.\n\nFinally, the problem asks for an enumeration of at least three scientifically plausible factors that can cause inter-patient variability in subcutaneous bioavailability ($F$) for monoclonal antibodies or fusion proteins. The absorption of large molecules like antibodies from the subcutaneous space is a complex process primarily mediated by the lymphatic system, not direct entry into blood capillaries. Variability in $F$ arises from differences in the physiological environment of the subcutaneous tissue and the efficiency of lymphatic transport among individuals.\n\n1.  **Function and Anatomy of the Lymphatic System:** The primary route of absorption for monoclonal antibodies from the subcutaneous space is via lymphatic vessels. Inter-patient variability in lymphatic drainage capacity—due to differences in the density of lymphatic capillaries at the injection site, lymphatic flow rates, or the patency of lymphatic vessels—can significantly alter the rate and extent of antibody absorption. Conditions such as local edema, inflammation, or underlying subclinical lymphatic dysfunction can impair this process and thus lower bioavailability ($F$).\n\n2.  **Local Catabolism and Cellular Uptake:** Before reaching the systemic circulation, the antibody is exposed to the environment of the subcutaneous interstitial space. This space contains various proteases and resident immune cells (e.g., macrophages, dendritic cells). Inter-patient differences in the concentration and activity of local degradative enzymes or in the phagocytic activity of local cells can lead to variable extents of pre-systemic degradation or clearance of the antibody. This local catabolism reduces the fraction of the dose that is available for absorption, directly impacting $F$.\n\n3.  **Composition and Physicochemical Properties of the Subcutaneous Extracellular Matrix (ECM):** The subcutaneous tissue is a complex network of collagen, elastin, and glycosaminoglycans (like hyaluronic acid) that form the ECM. The density, hydration, and charge of this matrix can impede the diffusion of a large molecule like an antibody toward the lymphatic vessels. Inter-patient variability in ECM composition, influenced by factors such as age, body composition (adiposity), hydration status, and certain disease states (e.g., diabetes), can lead to differences in antibody transit time and, consequently, variable exposure to local catabolic processes, altering the overall bioavailability.",
            "answer": "$$ \\boxed{1170} $$"
        },
        {
            "introduction": "In many clinical situations, it is necessary to achieve a therapeutic drug concentration rapidly, which is accomplished by administering an initial, large \"loading dose.\" While a simple calculation might involve just the volume of distribution ($V$), the reality for high-affinity biologics is more complex due to Target-Mediated Drug Disposition (TMDD), where a significant portion of the dose binds to its pharmacological target. This advanced exercise challenges you to derive a loading dose formula that accounts not only for filling the plasma volume but also for saturating the target, providing a more accurate model for initiating therapy .",
            "id": "4929104",
            "problem": "A biotechnology company plans to administer a monoclonal antibody by intravenous bolus into the central compartment and wishes to achieve a target free plasma concentration $C^{*}$ rapidly. Assume an initial single-compartment, linear pharmacokinetic system with instantaneous mixing and no elimination on the timescale of interest for the loading step. The central volume of distribution is $V$. Later, you will incorporate Target-Mediated Drug Disposition (TMDD), defined here as high-affinity, capacity-limited binding of the drug to a pharmacological target that alters the drug’s disposition, and assume the target is soluble in plasma, binds the drug in a $1:1$ stoichiometry, and achieves rapid binding equilibrium characterized by a dissociation constant $K_{D}$ and a total target concentration $R_{T}$.\n\nTasks:\n- Using fundamental definitions and mass balance, derive the general expression for the loading dose required to instantaneously achieve the free plasma concentration $C^{*}$ under linear pharmacokinetics.\n- Extend your derivation to include TMDD at rapid equilibrium in plasma, and obtain an analytical expression for the adjusted loading dose that maintains the free drug concentration at $C^{*}$ when binding to the soluble target is present. Express this adjusted dose in mass units, explicitly accounting for the monoclonal antibody molecular weight $M_{W}$.\n- Evaluate your adjusted loading dose for the following scientifically plausible parameters: $V = 4.0\\ \\mathrm{L}$, $C^{*} = 100\\ \\mathrm{mg/L}$, $M_{W} = 150 \\times 10^{3}\\ \\mathrm{g/mol}$, $R_{T} = 5.0 \\times 10^{-9}\\ \\mathrm{mol/L}$, and $K_{D} = 5.0 \\times 10^{-10}\\ \\mathrm{mol/L}$. Express the final dose in milligrams and round your answer to four significant figures.",
            "solution": "The problem requires the derivation of loading dose expressions for a monoclonal antibody, first under linear pharmacokinetics and then including target-mediated drug disposition (TMDD), followed by a numerical evaluation.\n\n**Task 1: Loading Dose under Linear Pharmacokinetics**\n\nIn a single-compartment model with intravenous bolus administration and instantaneous mixing, the loading dose ($D_L$) is the amount of drug required to instantaneously achieve a desired plasma concentration. The central volume of distribution ($V$) is defined as the proportionality constant relating the amount of drug in the body to the concentration in plasma. For a target free plasma concentration, $C^{*}$, the relationship is:\n$$C^{*} = \\frac{\\text{Amount of drug in the compartment}}{\\text{Volume of distribution}}$$\nBy definition, under linear pharmacokinetics without any binding phenomena, all drug in the compartment is considered free. Therefore, the amount of drug in the compartment is equal to the loading dose, $D_L$.\n$$C^{*} = \\frac{D_L}{V}$$\nRearranging this equation gives the general expression for the loading dose required to achieve the free plasma concentration $C^{*}$ under linear pharmacokinetics:\n$$D_L = C^{*} V$$\nThis expression represents the mass of drug that must be administered to fill the central volume $V$ to the target concentration $C^{*}$.\n\n**Task 2: Adjusted Loading Dose with TMDD**\n\nWhen we introduce Target-Mediated Drug Disposition (TMDD) as a rapid, $1:1$ equilibrium binding to a soluble target in plasma, the total amount of drug in the central compartment is the sum of the free drug and the drug bound to the target. The total loading dose, $D_{L, \\text{TMDD}}$, must account for both forms.\n$$D_{L, \\text{TMDD}} = (\\text{mass of free drug}) + (\\text{mass of bound drug})$$\nThe mass of free drug required to achieve the free concentration $C^{*}$ in the volume $V$ is, as derived above, $C^{*}V$.\n\nTo find the mass of bound drug, we must analyze the binding equilibrium. Let $[C]$ be the molar concentration of free drug, $[R]$ be the molar concentration of the free target, and $[RC]$ be the molar concentration of the drug-target complex. The dissociation constant, $K_D$, is defined as:\n$$K_D = \\frac{[C][R]}{[RC]}$$\nThe total target concentration, $R_T$, is the sum of free and bound target:\n$$R_T = [R] + [RC]$$\nFrom this, we can express the free target concentration as $[R] = R_T - [RC]$. Substituting this into the $K_D$ expression:\n$$K_D = \\frac{[C](R_T - [RC])}{[RC]}$$\nWe can now solve for the concentration of the bound complex, $[RC]$, in terms of the free drug concentration $[C]$ and the system parameters $R_T$ and $K_D$:\n$$K_D [RC] = [C]R_T - [C][RC]$$\n$$[RC](K_D + [C]) = [C]R_T$$\n$$[RC] = \\frac{R_T [C]}{K_D + [C]}$$\nThe problem requires achieving a specific free drug concentration in mass units, $C^{*}$. To use the above molar-based equation, we must convert $C^{*}$ to its molar equivalent, $[C]^{*}$, using the molecular weight, $M_W$:\n$$[C]^{*} = \\frac{C^{*}}{M_W}$$\nSubstituting $[C]^{*}$ for $[C]$, the concentration of the drug-target complex at the desired free drug concentration is:\n$$[RC] = \\frac{R_T (C^{*}/M_W)}{K_D + (C^{*}/M_W)}$$\nThe mass of the bound drug in the volume $V$ is the molar concentration of the complex, $[RC]$, multiplied by the volume, $V$, and the molecular weight of the drug, $M_W$:\n$$\\text{mass of bound drug} = [RC] \\cdot V \\cdot M_W$$\nSubstituting the expression for $[RC]$:\n$$\\text{mass of bound drug} = \\left( \\frac{R_T (C^{*}/M_W)}{K_D + (C^{*}/M_W)} \\right) V M_W$$\nThe total adjusted loading dose, $D_{L, \\text{TMDD}}$, is the sum of the free and bound drug masses:\n$$D_{L, \\text{TMDD}} = C^{*}V + \\left( \\frac{R_T (C^{*}/M_W)}{K_D + (C^{*}/M_W)} \\right) V M_W$$\nThis is the analytical expression for the adjusted loading dose.\n\n**Task 3: Numerical Evaluation**\n\nWe are given the following parameters:\n$V = 4.0\\ \\mathrm{L}$\n$C^{*} = 100\\ \\mathrm{mg/L}$\n$M_{W} = 150 \\times 10^{3}\\ \\mathrm{g/mol}$\n$R_{T} = 5.0 \\times 10^{-9}\\ \\mathrm{mol/L}$\n$K_{D} = 5.0 \\times 10^{-10}\\ \\mathrm{mol/L}$\n\nFirst, we must ensure all units are consistent. The final dose is required in milligrams ($\\mathrm{mg}$), so we will convert $M_W$ to $\\mathrm{mg/mol}$:\n$$M_W = 150 \\times 10^{3}\\ \\mathrm{g/mol} = 150 \\times 10^{3} \\times 10^3\\ \\mathrm{mg/mol} = 150 \\times 10^{6}\\ \\mathrm{mg/mol}$$\n\nThe total dose is the sum of two components:\n\n1.  **Dose for free drug (linear component):**\n    $$D_{\\text{free}} = C^{*}V = (100\\ \\mathrm{mg/L}) \\cdot (4.0\\ \\mathrm{L}) = 400\\ \\mathrm{mg}$$\n\n2.  **Dose for bound drug (TMDD component):**\n    We first calculate the target molar concentration of free drug, $[C]^{*}$:\n    $$[C]^{*} = \\frac{C^{*}}{M_W} = \\frac{100\\ \\mathrm{mg/L}}{150 \\times 10^{6}\\ \\mathrm{mg/mol}} = \\frac{1}{1.5 \\times 10^6}\\ \\mathrm{mol/L} \\approx 6.66... \\times 10^{-7}\\ \\mathrm{mol/L}$$\n    Next, we calculate the molar concentration of the drug-target complex, $[RC]$:\n    $$[RC] = \\frac{R_T [C]^{*}}{K_D + [C]^{*}} = \\frac{(5.0 \\times 10^{-9}\\ \\mathrm{mol/L}) \\cdot (6.66... \\times 10^{-7}\\ \\mathrm{mol/L})}{(5.0 \\times 10^{-10}\\ \\mathrm{mol/L}) + (6.66... \\times 10^{-7}\\ \\mathrm{mol/L})}$$\n    $$[RC] = \\frac{3.33... \\times 10^{-15}\\ (\\mathrm{mol/L})^2}{6.6716... \\times 10^{-7}\\ \\mathrm{mol/L}} \\approx 4.99625... \\times 10^{-9}\\ \\mathrm{mol/L}$$\n    Now, we find the mass of the bound drug:\n    $$D_{\\text{bound}} = [RC] \\cdot V \\cdot M_W$$\n    $$D_{\\text{bound}} = (4.99625... \\times 10^{-9}\\ \\mathrm{mol/L}) \\cdot (4.0\\ \\mathrm{L}) \\cdot (150 \\times 10^{6}\\ \\mathrm{mg/mol})$$\n    $$D_{\\text{bound}} = (4.99625... \\times 10^{-9}) \\cdot (600 \\times 10^{6})\\ \\mathrm{mg} = 2997.75 \\times 10^{-3}\\ \\mathrm{mg} = 2.99775...\\ \\mathrm{mg}$$\n\n3.  **Total adjusted loading dose:**\n    $$D_{L, \\text{TMDD}} = D_{\\text{free}} + D_{\\text{bound}} = 400\\ \\mathrm{mg} + 2.99775...\\ \\mathrm{mg} = 402.99775...\\ \\mathrm{mg}$$\n    Rounding the result to four significant figures, we get $403.0\\ \\mathrm{mg}$.",
            "answer": "$$\\boxed{403.0}$$"
        }
    ]
}